Dr. Reddy’s Laboratories has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the United States market approved by the US Food and Drug Administration (USFDA).
The Xenazine brand and generic had US sales of around $322 million MAT for the most recent twelve months ending in November 2017 according to IMS Health.
The company’s Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112. Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
